PG
PGNY.US Progyny Inc
- Market cap
- USD 2.74B
- P/E
- 33.2x
- P/B
- 6.44x
- ROE
- 25.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PGNY.US undervalued?
Graham numberThe Graham number of Progyny Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Progyny Inc fundamental analysis
No fundamental analysis for Progyny Inc yet.
Progyny Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Progyny Inc
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the…
Full company profileProgyny Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Progyny Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 48.6M | 105M | 230M | 345M | 501M | 787M | 1.09B | 1.17B | 1.29B | 1.36B |
| Gross Profit | 7.40M | 19.4M | 45.5M | 70.1M | 112M | 167M | 239M | 253M | 304M | 341M |
| Operating Income | -11.0M | -3.45M | 9.68M | 8.35M | 32.3M | 23.3M | 62.2M | 67.5M | 85.3M | 147M |
| EBITDA | -9.45M | -1.57M | 11.8M | 10.3M | 33.7M | 26.0M | 73.0M | 86.4M | 100M | 162M |
| Net Income | -12.5M | 661K | -8.57M | 46.5M | 65.8M | 30.4M | 62.0M | 54.3M | 58.5M | 105M |
| EPS | -2.19 | 0.01 | -0.10 | 0.47 | 0.66 | 0.30 | 0.62 | 0.57 | 0.65 | 1.29 |
| Balance Sheet | ||||||||||
| Total Assets | 35.0M | 41.3M | 150M | 254M | 358M | 543M | 757M | 607M | 742M | 676M |
| Total Liabilities | 24.3M | 30.2M | 36.2M | 87.0M | 106M | 166M | 203M | 185M | 226M | 262M |
| Shareholders' Equity | 10.7M | 11.1M | 114M | 167M | 252M | 377M | 553M | 422M | 516M | 414M |
| Cash & Short-term Investments | 4.69M | 127K | 80.4M | 109M | 119M | 189M | 371M | 228M | 310M | 196M |
| Total Debt | 5.19M | 253K | - | 9.55M | 8.65M | 7.71M | 19.4M | 19.3M | 27.7M | 21.7M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -9.47M | 2.27M | -1.53M | 36.2M | 26.0M | 80.4M | 189M | 179M | 210M | 265M |
| Capital Expenditure | 612K | 579K | 2.96M | 1.04M | 2.13M | 3.24M | 3.64M | 5.41M | 18.4M | 37.7M |
| Free Cash Flow | -10.1M | 1.69M | -4.49M | 35.2M | 23.9M | 77.2M | 185M | 174M | 192M | 228M |
| Ratios | ||||||||||
| ROE | -116.5% | 5.9% | -7.5% | 27.8% | 26.1% | 8.1% | 11.2% | 12.9% | 11.3% | 25.3% |
| ROA | -35.6% | 1.6% | -5.7% | 18.3% | 18.4% | 5.6% | 8.2% | 9.0% | 7.9% | 15.5% |
| Net Profit Margin | -25.6% | 0.6% | -3.7% | 13.5% | 13.1% | 3.9% | 5.7% | 4.7% | 4.5% | 7.7% |
| Debt to Equity | 0.49x | 0.02x | - | 0.06x | 0.03x | 0.02x | 0.04x | 0.05x | 0.05x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Progyny Inc dividends
Progyny Inc has not paid dividends in the last 9 fiscal years.
Who owns Progyny Inc
- Insiders 2.26%
- Institutions 97.74%
- Public & others 0.00%
- Shares outstanding 73.6M
- Free float 67.2M
Top funds holding PGNY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 4.62M | 6.28% | +0.06% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.26M | 3.07% | +0.36% | Sep 2026 |
| Fidelity Small Cap Growth | 2.03M | 2.75% | +21.06% | Aug 2026 |
| Avantis US Small Cap Value ETF | 1.93M | 2.61% | 0.00% | Oct 2026 |
| iShares Russell 2000 ETF | 1.85M | 2.51% | 0.00% | Oct 2026 |
| CT (Lux) American Smaller Com 9U USD | 1.56M | 2.12% | -7.82% | Sep 2026 |
| Vanguard Small Cap Index | 1.56M | 2.11% | -3.99% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 1.25M | 1.69% | +77.94% | Sep 2026 |
| Touchstone Small Company A | 1.24M | 1.69% | -35.94% | Sep 2026 |
| CT American Smaller Coms(US) InstAccGBP | 1.08M | 1.46% | +5.31% | Sep 2026 |
| Fidelity Small Cap Growth K6 | 1.03M | 1.40% | +21.69% | Aug 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 866K | 1.18% | -7.38% | Sep 2026 |
| Fidelity Small Cap Index | 748K | 1.02% | +0.15% | Aug 2026 |
| Loomis Sayles Small Cap Growth Instl | 718K | 0.98% | 0.00% | Sep 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 704K | 0.96% | -0.05% | Oct 2026 |
| Vanguard Strategic Equity Inv | 696K | 0.95% | +43.42% | Sep 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 690K | 0.94% | -0.38% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 689K | 0.94% | -0.38% | Oct 2026 |
| Fidelity Small Cap Discovery | 546K | 0.74% | -2.04% | Aug 2026 |
| Vanguard Tax-Managed Small Cap Adm | 506K | 0.69% | 0.00% | Sep 2026 |
Top institutions holding PGNY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 11.6M | 15.75% | -3.32% | Jun 2026 |
| FMR Inc | 7.00M | 9.51% | +7.74% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 5.02M | 6.82% | -5.15% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.21M | 4.36% | -7.77% | Jun 2026 |
| State Street Corp | 3.02M | 4.10% | -1.86% | Jun 2026 |
| Ameriprise Financial Inc | 2.76M | 3.75% | -2.19% | Jun 2026 |
| American Century Companies Inc | 2.58M | 3.51% | +231.85% | Sep 2026 |
| Geode Capital Management, LLC | 1.97M | 2.67% | -3.61% | Jun 2026 |
| Citadel Advisors Llc | 1.79M | 2.42% | 0.00% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.77M | 2.41% | +5.05% | Sep 2026 |
| Fort Washington Investment Advisors Inc | 1.64M | 2.22% | -35.78% | Sep 2026 |
| Soleus Capital Management, L.P. | 1.60M | 2.18% | -22.50% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.54M | 2.09% | -32.86% | Jun 2026 |
| Wellington Management Company LLP | 1.50M | 2.03% | -34.57% | Jun 2026 |
| Easterly Investment Partners. | 1.19M | 1.62% | 0.00% | Sep 2026 |
| Disciplined Growth Investors Inc | 1.18M | 1.60% | +105.66% | Jun 2026 |
| Loomis, Sayles & Company LP | 1.08M | 1.47% | +9.36% | Jun 2026 |
| Jane Street Group LLC | 1.06M | 1.44% | +614.12% | Jun 2026 |
| LSV Asset Management | 989K | 1.34% | +10.43% | Sep 2026 |
| Charles Schwab Investment Management Inc | 954K | 1.30% | +19.46% | Jun 2026 |
Progyny Inc company profile
- Company name
- Progyny Inc
- Ticker
- PGNY.US
- Exchange
- USA Stocks
- Listed since
- Oct 25, 2019
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 835
- Fiscal year end
- December
- Address
- 1359 Broadway, New York, NY, United States, 10018
- Phone
- 212 888 3124
- Website
- progyny.com
About Progyny Inc
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Progyny Inc management
10- Mr. David J. Schlanger J.D.Executive Chairman · born 1959
- Mr. Peter Anevski CPACEO & Director · born 1967
- Mr. Mark S. Livingston CPAChief Financial Officer · born 1966
- Ms. Melissa B. CummingsChief Operating Officer · born 1970
- Ms. Allison SwartzExecutive VP, General Counsel & Secretary · born 1990
- Mr. Geoffrey ClappChief Product Officer · born 1974
- Mr. Steven LeistChief Technology Officer
- Mr. James HartVice President of Investor Relations
- Ms. Risa FisherChief Marketing Officer
- Ms. Cassandra PrattChief Human Resources Officer